Valneva SE
Business
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company offers three marketed travel vaccines—IXIARO (Japanese encephalitis), DUKORAL (cholera and LT-ETEC), and IXCHIQ (chikungunya)—plus a clinical pipeline including VLA15 (Lyme disease, in Phase 3 with Pfizer), S4V2 (Shigella, Phase 2), VLA1601 (Zika, Phase 1), and pre-clinical candidates. Valneva operates manufacturing facilities in Scotland, Sweden, and Austria, and distributes products through owned commercial operations in multiple territories and partnerships with specialized distributors.
Summary from 20-F filed 2026-03-17
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-115.19M |
| Total assets | $398.84M |
| Total liabilities | $292.67M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Valneva SE's CIK number?
Valneva SE's SEC CIK number is 0001836564 (1836564). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Valneva SE's SEC filings?
All of Valneva SE's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.